Search

Author/Creator Felip, E

1. 121PLungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients. (23rd October 2018)

Authors:
Garrido Lopez, P; Felip, E; Paz-Ares, L; Majem, M; Moran, T; Gonzalez-Larriba, J L; Bosch Barrera, J; Trigo Perez, J M; Garcia Campelo, M R; Sanchez Torres, J M; Isla, D; Vinolas Segarra, N; Camps, C; Insa Molla, A; Juan Vidal, O J; Massutí, B; Paredes Lario, A; Artal-Cortes, A; Lopez-Brea Piquer...
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:
Santoro, A; Su, W-C; Navarro, A; Simonelli, M; Yang, J C-H; Ardizzoni, A; Barlesi, F; Kang, J H; Didominick, S; Abdelhady, A; Goswami, B; Crystal, A; Felip, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1399PImpact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:
Peters, S; Shaw, A T; Besse, B; Felip, E; Solomon, B J; Soo, R A; Bearz, A; Gadgee, S M; Lin, C-C; Kao, S; Seto, T; Masters, E T; Abbattista, A; Clancy, J S; Thurm, H; Reisman, A; Camidge, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018)

Authors:
Rodriguez Abreu, D; Garassino, M C; Esteban, E; Speranza, G; Felip, E; Domine, M; Hochmair, M J; Powell, S F; Cheng, S Y-S; Bischoff, H; Peled, N; Hui, R; Reck, M; Garon, E B; Boyer, M; Grossi, F; Jennens, R; Yang, J; Pietanza, M C; Gadgeel, S M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 167P Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts). (15th December 2019)

Authors:
Hernando-Calvo, A; Mirallas, O; Marmolejo, D; Felip, E; Garralda, E; Javierre, G Villacampa; Feliu, B; Martínez, S; Gutierrez, R; Dienstmann, R; Braña, I
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 22P Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy. (15th December 2019)

Authors:
Garcia, I Matos; Moreno, A; Arenillas, C; Carbo, C Hierro; Munoz-Cosuelo, E; Martin-Liberal, J; Braña, I; Villar, M Vieito; Azaro, A; Gadea, O Saavedra Santa; Gonzalez, I Gardeazabal; Javier, R; Roger, B; Elez, E; Felip, E; Dienstmann, R; Gros, A; Tabernero, J; Toledo, R D A; Garralda, E
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 493OTepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data. (25th November 2018)

Authors:
Sakai, H; Felip, E; Cortot, A B; Veillon, R; Griesinger, F; Patel, J; Horn, L; Mazieres, J; De Castro Carpeno, J; Morise, M; Sakamoto, T; Bruns, R; Scheele, J; Straub, J; Paik, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 532TiPCANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC. (24th November 2019)

Authors:
Tan, D S W; Kim, T M; Solomon, B J; Tan, W L; Yu, C-J; Geater, S; De Castro, G; Greystoke, A; Felip, E; Johnson, B E; Deudon, S; Louveau, A-L; Passos, V Q; Cho, B C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 62OTepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. (24th November 2019)

Authors:
Park, K; Felip, E; Veillon, R; Cortot, A; Mazieres, J; Sakai, H; Reinmuth, N; Viteri, S; Chen, Y-M; Han, J-Y; Jang, T-W; Morise, M; Sakamoto, T; Tokito, T; Cho, B C; Bruns, R; Scheele, J; Straub, J; Le, X; Paik, P K
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗